Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type.
Interest in HER2-low breast cancer has grown in recent years due to advancements in novel anti-HER2 antibody-drug conjugates. This study examined the impact of HER2-low expression on survival outcomes in triple-negative breast cancer (TNBC) of high-grade special histological type (ST) and no special...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0325715 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849688772473520128 |
|---|---|
| author | Claudia Grosse Petar Noack Alexandra Grosse Heike Kathleen Schwarz Peter Schrenk Heike Frauchiger-Heuer Rupert Langer Zsuzsanna Varga |
| author_facet | Claudia Grosse Petar Noack Alexandra Grosse Heike Kathleen Schwarz Peter Schrenk Heike Frauchiger-Heuer Rupert Langer Zsuzsanna Varga |
| author_sort | Claudia Grosse |
| collection | DOAJ |
| description | Interest in HER2-low breast cancer has grown in recent years due to advancements in novel anti-HER2 antibody-drug conjugates. This study examined the impact of HER2-low expression on survival outcomes in triple-negative breast cancer (TNBC) of high-grade special histological type (ST) and no special type (NST) and investigated the prognostic significance of TNBC subtype (high-grade ST vs. NST) within HER2 0 and HER2-low expression subgroups. Clinicopathological and survival data of 504 patients with stage I-III TNBC, with or without neoadjuvant chemotherapy (NAC), were analyzed, including 400 patients with TNBC NST and 104 patients with high-grade TNBC ST. HER2-low status was not identified as an independent prognostic factor for survival in the overall cohort, nor within the high-grade TNBC ST and TNBC NST subgroups. Among patients who did not receive NAC, TNBC subtype (high-grade ST vs. NST) was independently associated with DDFS and DFS in the HER2 0 subgroup, but not in the HER2-low subgroup. Patients with HER2 0 high-grade TNBC ST exhibited significantly worse OS (p = 0.008), DDFS (p < 0.001), and DFS (p < 0.001) compared to those with HER2 0 TNBC NST. Among patients with either HER2 0 or HER2-low tumors treated with NAC, no significant survival difference was observed between high-grade TNBC ST and TNBC NST. These findings suggest that the prognostic impact of TNBC subtype (high-grade ST vs. NST) on survival outcomes may be modulated by HER2 status in a subset of TNBC patients. |
| format | Article |
| id | doaj-art-18d19a6468cc4375b46681da627bdb6e |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-18d19a6468cc4375b46681da627bdb6e2025-08-20T03:21:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032025-01-01206e032571510.1371/journal.pone.0325715Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type.Claudia GrossePetar NoackAlexandra GrosseHeike Kathleen SchwarzPeter SchrenkHeike Frauchiger-HeuerRupert LangerZsuzsanna VargaInterest in HER2-low breast cancer has grown in recent years due to advancements in novel anti-HER2 antibody-drug conjugates. This study examined the impact of HER2-low expression on survival outcomes in triple-negative breast cancer (TNBC) of high-grade special histological type (ST) and no special type (NST) and investigated the prognostic significance of TNBC subtype (high-grade ST vs. NST) within HER2 0 and HER2-low expression subgroups. Clinicopathological and survival data of 504 patients with stage I-III TNBC, with or without neoadjuvant chemotherapy (NAC), were analyzed, including 400 patients with TNBC NST and 104 patients with high-grade TNBC ST. HER2-low status was not identified as an independent prognostic factor for survival in the overall cohort, nor within the high-grade TNBC ST and TNBC NST subgroups. Among patients who did not receive NAC, TNBC subtype (high-grade ST vs. NST) was independently associated with DDFS and DFS in the HER2 0 subgroup, but not in the HER2-low subgroup. Patients with HER2 0 high-grade TNBC ST exhibited significantly worse OS (p = 0.008), DDFS (p < 0.001), and DFS (p < 0.001) compared to those with HER2 0 TNBC NST. Among patients with either HER2 0 or HER2-low tumors treated with NAC, no significant survival difference was observed between high-grade TNBC ST and TNBC NST. These findings suggest that the prognostic impact of TNBC subtype (high-grade ST vs. NST) on survival outcomes may be modulated by HER2 status in a subset of TNBC patients.https://doi.org/10.1371/journal.pone.0325715 |
| spellingShingle | Claudia Grosse Petar Noack Alexandra Grosse Heike Kathleen Schwarz Peter Schrenk Heike Frauchiger-Heuer Rupert Langer Zsuzsanna Varga Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type. PLoS ONE |
| title | Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type. |
| title_full | Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type. |
| title_fullStr | Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type. |
| title_full_unstemmed | Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type. |
| title_short | Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type. |
| title_sort | prognostic impact of her2 low expression in triple negative breast cancer of high grade special histological type and no special type |
| url | https://doi.org/10.1371/journal.pone.0325715 |
| work_keys_str_mv | AT claudiagrosse prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT petarnoack prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT alexandragrosse prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT heikekathleenschwarz prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT peterschrenk prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT heikefrauchigerheuer prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT rupertlanger prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype AT zsuzsannavarga prognosticimpactofher2lowexpressionintriplenegativebreastcancerofhighgradespecialhistologicaltypeandnospecialtype |